A recent study identifies a novel drug targeting GABA production that may offer hope for effective PTSD treatment, addressing long-standing memory issues.
Post-traumatic stress disorder (PTSD) is notoriously challenging to treat, primarily because patients often struggle to erase traumatic memories, leading to persistent anxiety and emotional distress. Traditional therapies, especially those focused on serotonin levels, provide limited relief to many sufferers. However, researchers at the Institute for Basic Science (IBS) and Ewha Womans University have made strides in understanding the underlying mechanisms of this condition, uncovering a promising new treatment strategy.
Dr. C. Justin Lee from IBS and Professor In Kyoon Lyoo at Ewha led a team that pinpointed a significant contributor to PTSD: an excess of gamma-aminobutyric acid (GABA), which is primarily produced by astrocytes in the brain. These supporting cells, while crucial for neural health, appear to impede the brain's ability to forget fear-related memories in PTSD patients, a finding that could reshape treatment approaches.
The researchers demonstrated that a reversible MAOB (monoamine oxidase B) inhibitor, known as KDS2010, can effectively mitigate PTSD-like symptoms in mouse models by blocking abnormal GABA production. This drug, which has successfully cleared Phase 1 safety trials in humans, could represent a vital new direction for clinical PTSD therapies.
During their investigation, the team analyzed brain scans of over 380 participants, revealing that those with PTSD exhibited elevated GABA levels and diminished blood flow in the medial prefrontal cortex (mPFC)—a critical area for fear regulation. Notably, a reduction in GABA correlated with clinical improvements, underscoring its potential as a target for therapeutic intervention.
To establish the causative role of elevated GABA in PTSD, the researchers examined human brain tissue and deployed mouse models that mimic PTSD symptoms. They confirmed that astrocytes were responsible for producing excessive GABA via MAOB. This abnormal GABA production negatively affected neural circuits, impairing the brain's natural memory extinction processes.
Administering KDS2010 resulted in a reversal of these effects: the mice displayed normalized neural activity, reduced GABA levels, and regained the ability to suppress fear responses. These results confirm the central role of astrocytic MAOB in the pathology of PTSD and highlight MAOB inhibition as a promising therapeutic target.
A significant aspect of this research involved linking observational findings in patients with laboratory results. Adopting a reverse translational approach, the scientists started with human imaging studies and worked backward to correlate these results with the cellular mechanisms involved. This method not only helped clarify how astrocytes contribute actively to psychiatric symptoms but also points to the necessity of broadening our understanding of cell types beyond neurons.
Dr. Woojin Won, a key researcher in the study, stated, "We are the first to identify astrocyte-derived GABA as a pivotal pathological factor driving the fear extinction deficit in PTSD." This groundbreaking research paves the way for innovative therapeutic strategies involving MAOB inhibitors, potentially extending beyond PTSD to other neuropsychiatric conditions like depression and panic disorder.
Dr. Lee emphasized the value of their reverse translational approach, stating, “This work highlights the successful translation of clinical findings into basic science, leading to identification of new therapeutic pathways.” Researchers are now poised to explore astrocyte-targeted therapies across a range of neuropsychiatric disorders, with KDS2010 moving into Phase 2 clinical trials. The prospects for patients who have not responded to established treatments are becoming increasingly hopeful.
Materials provided by Institute for Basic Science. Note: Content may be edited for style and length.
New Fat-Dissolving Shot Cuts Hidden Visceral Fat in Early Human Trials
Aging Cells May Be Hiding From the Immune System – Scientists Think They Know How
Study Finds Exercise May Be a Surprisingly Powerful Treatment for Pain
Scientists Discover “Pac-Man Enzyme” That Eats Plastic
Stay informed with ScienceDaily's free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:
Keep up to date with the latest news from ScienceDaily via social networks:
Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Discussion
Sign in to join the discussion.